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Rationale
Janus kinases (JAK) transduce
multiple cytokine receptors reported
to play an important role in asthma
and COPD. VR588 is a selective and
potent pan-JAK inhibitor suited to
inhalation delivery and therefore may
represent a new opportunity for the
treatment of these conditions. These
studies were designed to characterise
the in-vitro kinase inhibition profile of
VR588 and to determine its
selectivity versus non-JAK kinases.
Methods
Comparison of kinase inhibitory
activity was conducted in a non-cell
(Z’Lyte™ Florescence assay) and in
cell based assays using stimulation of
human whole blood (IL-2 stimulated
INFγ production and JAK1/JAK3 and
pSTATa/b activation and IL-6
stimulated pSTAT3 to assess JAK1,
JAK2 and Tyk2 activity).
VR588 potently inhibited JAK 1, 2, 3
and Tyk2 kinases in the non-cell
based assay. Low nM potency was
achieved against all JAK kinases.
Results I
In the same non-cell based assay
VR588 showed poor inhibitory
activity against non–JAK kinases
including FLT3, PDGFB, JNK2 and Syk.
Results II
Results III
This potent and broad JAK inhibition
was confirmed in the cell based
assays with inhibition of IL-2
stimulated INFγ, IL-2 stimulated
pSTATa/b & IL-6 stimulated pSTAT3.
Results IV
The range of these demonstrated
between 14 to 128 fold lower
affinity than binding to Jak2.
Conclusion
VR588 represents a potent and
balanced inhibitor of the JAKs and
the lack of off-target effects
mitigates the potential for
unwanted kinase activity. These
results suggest VR588 may have
utility as a pharmacological
treatment of asthma and COPD and
have prompted the characterisation
of absorption, distribution,
metabolism, and excretion (ADME)
and in-vivo efficacy via the inhaled
route.
Results V
TREEspotTM visualisation of kinase
binding, where larger circles indicate
higher affinity binding.
In addition, the selectivity of VR588
(1mM) against a panel of 93 human
kinases was assessed using a
competitive displacement assay.
VR588 displaced DNA-tagged kinase
from its immobilised active site
ligand; binding to the kinases was
determined by quantitative PCR
(KinomeSCAN™).
VR588
1000nM
Kinase inhibition IC50 (nM)
Kinase VR588 Ruxolitinib
(INCB-
18424)
Fostamatinib
(R-406)
Tofacitinib
(CP-
690550)
FLT3 247 - - -
PDGFB 2350 - - -
JNK2 4000 - - -
Syk 8900 >3000 66 >10000
Diagram of Z’Lyte™ Florescence assay method
KinomeSCAN validation assay showing binding
of 38 kinase inhibitors versus a panel of 287
human protein kinases and 3 lipid kinases.
S(35) = (number of non-mutant kinases with
%Ctrl<35%)/290 kinases. Compounds
approved for human use (as of August 2007)
are highlighted in grey. The selectivity score
S(35) for VR588 against 93 kinases was 0.144.
Diagram of KinomeSCAN™ method
Results IV
Selectivity assay against a panel of
human kinases revealed no relevant
off- target effects. Of 93 non-mutant
human kinases tested only 10 non-
JAK kinases demonstrated binding of
<35% of control.
IC50 values (nM)
VR588 Ruxolitinib
(INCB-
18424)
Tofacitinib
(CP-
690550)
I-2-IFNγ production
(Jak1-Jak3)
209 394 188
IL-2-pSTATa/b
(Jak1-Jak3)
29 34 28
IL-6-pSTAT3 62 54 32
(Jak1-Jak2-Jak3)
Kinase inhibition IC50 (nM)
Kinase VR588 Ruxolitinib
(INCB-
18424)
Fostamatinib
(R-406)
Tofacitinib
(CP-
690550)
Jak3 2.1 59 75 4.7
Jak2 0.7 3.1 11.2 11.8
Jak1 4.2 5.2 136 9.1
Tyk2 6.0 1.2 11.2 19.5
